237 related articles for article (PubMed ID: 2865029)
1. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
Reilly CS; Wood M; Koshakji RP; Wood AJ
Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
Quon CY; Gorczynski RJ
J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
Tobias JD; Sauder RA; Hirshman CA
Anesthesiology; 1990 Jul; 73(1):132-6. PubMed ID: 1972872
[TBL] [Abstract][Full Text] [Related]
5. Beta-receptor antagonism does not fully explain esmolol-induced hypotension.
Deegan R; Wood AJ
Clin Pharmacol Ther; 1994 Aug; 56(2):223-8. PubMed ID: 7914845
[TBL] [Abstract][Full Text] [Related]
6. Esmolol infusion versus propranolol infusion: effects on heart rate and blood pressure in healthy volunteers.
Muller MD; Ahmad TA; Vargas Pelaez AF; Proctor DN; Bonavia AS; Luck JC; Maman SR; Ross AJ; Leuenberger UA; McQuillan PM
J Appl Physiol (1985); 2017 Mar; 122(3):511-519. PubMed ID: 28035016
[TBL] [Abstract][Full Text] [Related]
7. Esmolol: effects on isoprenaline- and exercise-induced cardiovascular stimulation in conscious dogs.
Fischer G; Grohs JG; Raberger G
Can J Physiol Pharmacol; 1990 Oct; 68(10):1322-8. PubMed ID: 1981854
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of esmolol for unstable angina pectoris.
Wallis DE; Pope C; Littman WJ; Scanlon PJ
Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
[TBL] [Abstract][Full Text] [Related]
9. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
10. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and antiarrhythmic effects of esmolol in children.
Trippel DL; Wiest DB; Gillette PC
J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
[TBL] [Abstract][Full Text] [Related]
12. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
[TBL] [Abstract][Full Text] [Related]
13. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous infusion of esmolol and propranolol on biventricular performance at rest and during exercise as assessed by quantitative radionuclide angiography.
Iskandrian AS; Hakki AH; Laddu A; Steck J; Saunders R; Kane-Marsch S; Morganroth J
Am J Cardiol; 1985 May; 55(11):1287-92. PubMed ID: 3993558
[TBL] [Abstract][Full Text] [Related]
15. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
16. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.
Howie MB; Hiestand DC; Zvara DA; Kim PY; McSweeney TD; Coffman JA
Anesth Analg; 1992 Nov; 75(5):805-10. PubMed ID: 1358003
[TBL] [Abstract][Full Text] [Related]
17. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations.
Motomura S; Hagihara A; Narumi Y; Hashimoto K
J Cardiovasc Pharmacol; 1998 Mar; 31(3):431-40. PubMed ID: 9514189
[TBL] [Abstract][Full Text] [Related]
18. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
[TBL] [Abstract][Full Text] [Related]
19. Effects of esmolol on airway function in patients with asthma.
Sheppard D; DiStefano S; Byrd RC; Eschenbacher WL; Bell V; Steck J; Laddu A
J Clin Pharmacol; 1986 Mar; 26(3):169-74. PubMed ID: 2870080
[TBL] [Abstract][Full Text] [Related]
20. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
